Levemir (insulin detemir) has been discontinued in the United States, leaving over 600,000 people with diabetes without the stability they depended on. Insulin is not a “one size fits all” medication — what works for one patient may not work for another. For many, Levemir was the only option that kept blood sugars safe, stable, and predictable. Its removal has forced patients into mid-care switches with no biosimilar alternative available.

When I was first diagnosed with diabetes, my A1C was 13 — dangerously high. Through lifestyle changes and the use of Levemir, I was able to bring my A1C down to 5.7, a safe and healthy range. Levemir wasn’t just another prescription; it was the difference between crisis and control. Thousands of other patients have similar stories, which is why removing this option puts lives at risk.

Every day without access to proven treatments raises the risk of blood sugar spikes, ER visits, long-term complications, and preventable harm. Patients deserve stability, choice, and continuity of care — not corporate decisions that jeopardize their health.

We call on Novo Nordisk, the FDA, and the U.S. Department of Health and Human Services to take immediate action to restore access to Levemir or ensure a safe, affordable biosimilar alternative is available without delay. Lives depend on it.